Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
Impact in
- Cancer Research 458
Classified as
- Journal
- Cancer Cell
In The Last Decade
doi.org/10.1016/j.ccr.2005.09.005 →Countries where authors are citing Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
This map shows the geographic impact of Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors more than expected).
Fields of papers citing Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
This network shows the impact of Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
About Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
This paper, published in 2005, received 1.4k indexed citations . Written by Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers and Douglas Hanahan covering the research area of Neurology, Molecular Biology and Cancer Research. It is primarily cited by scholars working on Molecular Biology (872 citations), Cancer Research (458 citations), Oncology (404 citations), Pulmonary and Respiratory Medicine (222 citations) and Epidemiology (117 citations). Published in Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1016/j.ccr.2005.09.005.